Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTX-4430 When Administered Orally to Cystic Fibrosis Patients for Fifteen Days
NCT01944735 is registered in ClinicalTrials.gov with Celtaxsys, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTX-4430 When Administered Orally to Cystic Fibrosis Patients for Fifteen Days
- Lead sponsor
- Celtaxsys, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 30, 2013
- Completion date
- November 30, 2014
- Enrollment
- 17 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.